1. Home
  2. SAGE

SAGE

Sage Therapeutics Inc.

Logo Sage Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 3:58pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Founded: 2010 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 928.0M IPO Year: 2014
Target Price: $21.47 AVG Volume (30 days): 996.4K
Analyst Decision: Hold Number of Analysts: 16
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -9.05 EPS Growth: N/A
52 Week Low/High: $15.28 - $59.99 Next Earning Date: 04-25-2024
Revenue: $86,455,000 Revenue Growth: 1024.84%
Revenue Growth (this year): -56.24% Revenue Growth (next year): 263.48%

Share on Social Networks: